Enoxaparin

Show simple item record

dc.contributor.author Padayachee, N.
dc.contributor.author Schoeman, N.
dc.contributor.author Schellack, Natalie
dc.date.accessioned 2022-07-29T06:55:25Z
dc.date.available 2022-07-29T06:55:25Z
dc.date.issued 2021-05
dc.description.abstract The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality. en_US
dc.description.department Pharmacology en_US
dc.description.uri http://www.sapj.co.za en_US
dc.identifier.citation Padayachee N., Schoeman N. & Schellack, N. 2021, 'Enoxaparin', SA Pharmaceutical Journal, vol. 88, no. 2, pp. 26-29, doi : 10.10520/ejc-mp_sapj_v88_n2_a7. en_US
dc.identifier.issn 2221-5875 (print)
dc.identifier.issn 2220-1017 (online)
dc.identifier.other 10.10520/ejc-mp_sapj_v88_n2_a7
dc.identifier.uri https://repository.up.ac.za/handle/2263/86582
dc.language.iso en en_US
dc.publisher Medpharm Publications en_US
dc.rights Medpharm Publications. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. en_US
dc.subject Enoxaparin en_US
dc.subject Coagulopathy en_US
dc.subject Factor Xa en_US
dc.subject Low-molecular weight heparin (LMWH) en_US
dc.subject COVID-19 pandemic en_US
dc.subject Coronavirus disease 2019 (COVID-19) en_US
dc.subject Thrombotic conditions en_US
dc.title Enoxaparin en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record